Skip to main content

Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024

  • Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2
  • GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8%
  • Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://cnw.fm/g0mZl). This follows the recent announcement of an applied research program to evaluate certain molecular characteristics of its patented DehydraTECH(TM) processed GLP-1 drug, semaglutide, related to its mode of action and performance. It also marks a significant milestone in the company’s 2024 research pipeline (https://cnw.fm/uGmp4).

At the beginning of the year, the company resolved to focus on GLP-1 studies for the calendar year, having shown positive results in an 8-week clinical study in 2023/24. This latest milestone followed its recent contract award and independent ethics review board approval in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.